Join

Compare · EPRX vs IMV

EPRX vs IMV

Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and IMV Inc. (IMV): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both EPRX and IMV operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
  • IMV carries a market cap of $89.5M.
  • EPRX has hit the wire 7 times in the past 4 weeks while IMV has been quiet.
  • EPRX has more recent analyst coverage (6 ratings vs 2 for IMV).
MetricEPRXIMV
Company
Eupraxia Pharmaceuticals Inc.
IMV Inc.
Price
$7.17-1.51%
$0.80+2.92%
Market cap
-
$89.5M
1M return
+1.13%
-
1Y return
+83.61%
-
Sector
Health Care
Health Care
Industry
Pharmaceuticals and Biotechnology
Pharmaceuticals and Biotechnology
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
7
0
Recent ratings
6
2
IMV

IMV Inc.

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Latest EPRX

Latest IMV